Based on 1 analyst offering 12 month price targets for Radiopharm Theranostics Ltd
Min Forecast
$15.00+268.55%
Avg Forecast
$15.00+268.55%
Max Forecast
$15.00+268.55%
Should I buy or sell RADX stock?
Based on 1 analyst offering ratings for Radiopharm Theranostics Ltd.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RADX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RADX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More
Be the first to know when Wall Street analysts revise their RADX stock forecasts and price targets.
Is Radiopharm Theranostics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: RADX) stock is to Strong Buy RADX stock.
Out of 1 analyst, 1 (100%) are recommending RADX as a Strong Buy, 0 (0%) are recommending RADX as a Buy, 0 (0%) are recommending RADX as a Hold, 0 (0%) are recommending RADX as a Sell, and 0 (0%) are recommending RADX as a Strong Sell.
What is RADX's earnings growth forecast for 2025-2025?
(NASDAQ: RADX) Radiopharm Theranostics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Radiopharm Theranostics's earnings in 2025 is -$25,688,349.
In 2025, RADX is forecast to generate -$21,729,608 in earnings, with the lowest earnings forecast at -$21,729,608 and the highest earnings forecast at -$21,729,608.
What is RADX's revenue growth forecast for 2025-2025?
(NASDAQ: RADX) Radiopharm Theranostics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Radiopharm Theranostics's revenue in 2025 is $1,058,411.
In 2025, RADX is forecast to generate $1,912,205,465 in revenue, with the lowest revenue forecast at $1,912,205,465 and the highest revenue forecast at $1,912,205,465.
What is RADX's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: RADX) forecast ROA is -37.37%, which is lower than the forecast US Biotechnology industry average of 95.74%.
What is RADX's Price Target?
According to 1 Wall Street analyst that have issued a 1 year RADX price target, the average RADX price target is $15.00, with the highest RADX stock price forecast at $15.00 and the lowest RADX stock price forecast at $15.00.
The Wall Street analyst predicted that Radiopharm Theranostics's share price could reach $15.00 by Mar 12, 2026. The average Radiopharm Theranostics stock price prediction forecasts a potential upside of 268.55% from the current RADX share price of $4.07.
What is RADX's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: RADX) Radiopharm Theranostics's current Earnings Per Share (EPS) is -$12.13. In 2025, RADX's EPS is forecast to hit -$0.01 (min: -$0.01, max: -$0.01).
What is RADX's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: RADX) forecast ROE is -64.94%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.